TearSolutions: Naturally Treating Dry Eye (225)
Tear Solutions

TearSolutions’ lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). 

The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.



Recent Posts

An Early Stage Investment Framework

An Investment Framework by Michael Schmanske Anyone who knows me, knows I have no choice…

MD Next Magazine – Premier Issue

We are pleased to introduce MD Next magazine as the newest channel in the AngelMD…

Late State VCs Moving Downstream

CB Insights shared the fact that some of the larger venture firms, who also happen…